Examples of 'trastuzumab emtansine' in a sentence
Meaning of "trastuzumab emtansine"
Trastuzumab emtansine: A targeted therapy medication used in the treatment of HER2-positive breast cancer, which combines the chemotherapy drug emtansine with the antibody trastuzumab
How to use "trastuzumab emtansine" in a sentence
Basic
Advanced
trastuzumab emtansine
Do not administer trastuzumab emtansine until.
Trastuzumab emtansine is administered intravenously.
The active substance is trastuzumab emtansine.
Discontinue trastuzumab emtansine if not resolving with standard treatment.
Patients were randomised to receive trastuzumab emtansine.
Trastuzumab emtansine was not studied in patients with severe hepatic impairment.
There is no known antidote for trastuzumab emtansine overdose.
Trastuzumab emtansine has not been studied in patients with platelet counts.
Continue treatment with trastuzumab emtansine.
Trastuzumab emtansine has not been studied in patients with severe hepatic impairment.
It is not known whether trastuzumab emtansine is excreted in human milk.
The median duration of response was not reached with trastuzumab emtansine vs.
Specific treatment for trastuzumab emtansine extravasation is unknown at this time.
Dedicated fertility studies have not been conducted with trastuzumab emtansine.
Patients treated with trastuzumab emtansine are at increased risk of developing left ventricular dysfunction.
See also
Schematic representation of trastuzumab emtansine.
In trastuzumab emtansine there is also a cytotoxic drug which is delivered into the cancer cell.
There are no data from the use of trastuzumab emtansine in pregnant women.
Reactions secondary to extravasation have been observed in clinical studies with trastuzumab emtansine.
The median PFS and OS for the trastuzumab emtansine group were.
No reproductive and developmental toxicology studies have been conducted with trastuzumab emtansine.
Do not administer trastuzumab emtansine in combination with chemotherapy 5.
It is recommended that platelet counts are monitored prior to each trastuzumab emtansine dose.
Do not substitute or combine trastuzumab emtansine with or for trastuzumab 4.
Kadcyla is a cancer medicine that contains the active substance trastuzumab emtansine.
Trastuzumab emtansine should be discontinued in case of life-threatening infusion reactions.
No fertility studies in animals have been performed to evaluate the effect of trastuzumab emtansine.
Trastuzumab emtansine dose should not be re-escalated after a dose reduction is made.
The population PK analysis showed that age did not affect the PK of trastuzumab emtansine.
There may be an interaction between trastuzumab emtansine and any of the following,.
Serious, anaphylactic reactions have been observed in clinical studies with trastuzumab emtansine.
By contrast, the administration of trastuzumab emtansine inhibited the growth of the tumor.
It must be verified that the non-proprietary name is trastuzumab emtansine.
No accumulation of trastuzumab emtansine was observed after repeated dosing of intravenous infusion every 3 weeks.
Currently two ADCs are marketed, brentuximab vedotin and trastuzumab emtansine.
Upon diagnosis of NRH, trastuzumab emtansine treatment must be permanently discontinued.
Dedicated embryo-foetal development studies have not been conducted in animals with trastuzumab emtansine.
Trastuzumab emtansine has the mechanisms of action of both trastuzumab and DM1.
Table 6 Tabulated list of ADRs in patients treated with trastuzumab emtansine.
Peripheral neuropathy Trastuzumab emtansine should be temporarily discontinued in patients experiencing Grade 3 or 4.
Table 3 Tabulated list of ADRs in patients treated with trastuzumab emtansine in clinical trials.
Trastuzumab emtansine has not been studied in patients with severe hepatic impairment Child-Pugh class C.
Biotransformation trastuzumab emtansine and DM1.
What Kadcyla contains · The active substance is trastuzumab emtansine.
The safety of trastuzumab emtansine has been evaluated in1871 breast cancer patients in clinical studies.
After reconstitution one vial of 8 mL solution contains 20 mg / mL of trastuzumab emtansine.
A total of 991 patients were randomised to trastuzumab emtansine or lapatinib plus capecitabine as follows.
In some embodiments, the anti-HER2 therapeutic agent is trastuzumab emtansine.
Do not administer trastuzumab emtansine until resolution £ Grade 2.
Left ventricular dysfunction was reported in 2.2 % of patients in clinical studies with trastuzumab emtansine.
You'll also be interested in:
Examples of using Trastuzumab
Show more
Trastuzumab can therefore lead to cardiac dysfunction
Typically used when trastuzumab is no longer working
Trastuzumab is commonly used until disease progression
